.png){kind=icon}
.png){kind=icon}
Return
Treating venous malformations with nanomedicines
.png){kind=icon}
PRE
AI
DOI：10.1080/17435889.2025.2573627.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Venous malformations (VMs) are congenital vascular anomalies that cause pain, bleeding, and functional impairment, yet current first-line therapies such as sclerotherapy and surgical resection are limited by complications and high recurrence rates. Nanomedicine provides a promising alternative by exploiting the enhanced permeation and retention (EPR)-like effect to achieve selective accumulation of nanoparticles (NPs) within VMs. Preclinical studies support the use of NPs not only for improved drug delivery but also for non-pharmacologic based treatment, such as photothermal therapy. Furthermore, active targeting strategies involving surface-functionalized NPs offer the potential for enhanced specificity and treatment efficacy. Despite these advances, clinical translation faces challenges such as heterogeneity in EPR efficiency, depth-limited delivery, and pediatric safety concerns. Continued efforts to create more effective, pediatric-specific drug delivery systems are essential for developing safer, more efficient, and minimally invasive nanomedicine therapy for patients with VMs.
Keywords:
Gold nanoparticles
Nanoparticles
Nanoshells
Pediatrics
Therapeutics